Startups
Edit
Tocagen
https://tocagen.com/Last activity: 20.02.2020
Probably Closed - Reference to Helena Study
No One Should Die of Cancer
Overview
Location
United States, California, San Diego
Employees
51-200
Total raised
$15K
Founded date
2007
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 24, 2019 | Why is glioblastoma such a tough nut to crack? | The latest letdowns came in just the last few months. In September, San Diego-based Tocagen announced that its Phase III study of the gene therapy and prodrug combination Toca 511 and Toca FC in recurrent GBM had failed to show an improveme... |
| May 9, 2019 | BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study | Shares of BMS were down 1.1 percent in Thursday morning trading on the New York Stock Exchange. Another Phase III study, CheckMate-548, evaluates Opdivo in combination with radiation and the drug temozolomide in MGMT-methylated GBM patients... |
| Apr 18, 2018 | CNS Pharma tries new therapeutic, financing approaches against glioblastoma | “You do temozolomide and radiation to shrink the tumor, and then you do surgery, and then you radiate the rest of the tumor, giving temozolomide,” said CNS Pharma’s CMO Sandra Silberman in a phone interview. “Then you just wait for the tumo... |
| Feb 24, 2017 | AstraZeneca gets a thumbs-up for ZS-9 in Europe; Tocagen wins a BTD for brain cancer drug | • AstraZeneca has won a recommendation for its closely-watched hyperkalemia drug ZS-9 from the EMA’s Committee for Medicinal Products for Human Use. AstraZeneca bought the drug from ZS Pharma in a $2.7 billion deal, but w... |
| Feb 9, 2016 | Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M | “We believe in having multiple antigens, not just one,” Brooks said. “We’re involved in bispecific and trispecific antigens.” So far, Aurora been operating largely on some $15 million in grant funding, from the NIH and various charities. It... |
| Feb 8, 2012 | Siemens partners with ViiV, Tocagen on new personalized medicine tests | An HIV/AIDS treatment developed by GlaxoSmithKline (NYSE:GSK) is now being studied with Siemens (NYSE:SI) to develop companion diagnostics that doctors can use to select patients appropriate for the treatment. The partnership with ViiV Heal... |
| Mar 8, 2010 | Tocagen, Developing Anti-Cancer Therapies, Close to Closing on $8M Round | Share Share on Facebook Share on Twitter LinkedIn Email Reprints San Diego’s Tocagen, a biotech developing gene therapy treatments for terminal cancers, says it has raised nearly $7.8 million from 75 investors in a Series D round that began... |
| Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M | A new contender is emerging in the glioblastoma space: Cambridge startup Aurora Biopharma is developing a CAR-T immunotherapy to treat this aggressive form of brain cancer. It’s looking to raise a $20 million Series A round, CEO Robert Broo... | |
| BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study | A study conducted by Bristol-Myers Squibb combining its immunotherapy agent with radiation in patients with the most aggressive form of brain cancer has failed, the drugmaker said. New York-based BMS said Thursday that its Phase III CheckMa... |
Show more
Reviews 0
FAQ about Tocagen
When was Tocagen founded?
Tocagen was founded in 2007.
How much funding has Tocagen raised?
Tocagen has raised $15K in total across 1 funding round.
What has the press written about Tocagen?
Parsers VC has collected 13 articles mentioning Tocagen, among them “Why is glioblastoma such a tough nut to crack?” (Dec 24, 2019) and “BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study” (May 9, 2019).
Is Tocagen still active?
Tocagen is probably closed: its latest activity on Parsers VC dates from Feb 20, 2020.